Dr. Robin Edwards and Dr. David Ferry join Dragonfly's Clinical Leadership Team

Six Dragonfly-developed drugs are presently in the clinic. WALTHAM, Mass., June 1, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc.,...

Dr. Joseph E. Eid joins Dragonfly Therapeutics as President of R&D

Dr. Eid joins Dragonfly after 20 years of clinical development experience at Roche, Merck and BMS including as team leader at Merck in...

Dragonfly Initiates Phase 2 Study of HER2 Targeting TriNKET™ DF1001

In Phase 1 DF1001 was well-tolerated and showed encouraging pharmacodynamic effects and clinical response, with tumor burden reductions...

Dragonfly Announces Multi-Target Expansion of Research Collaboration with AbbVie

Dragonfly and AbbVie expand their existing collaboration in oncology and autoimmune disease to develop additional drug candidates in...

Merck and Dragonfly, Together Again

This morning, investors in privately-held Dragonfly Therapeutics are thankful after Merck opted to license its second TriNKET...

Dragonfly gets Merck on second TriNKET candidate since 2018 collab

Dragonfly Therapeutics is doing better and better in getting Big Pharma on its TriNKET platform. First Celgene, then BMS, and now Merck —...

Dragonfly Therapeutics Announces Sixth Dragonfly Drug to be Licensed by Bristol Myers Squibb

The company announces its sixth drug licensed by Bristol Myers Squibb, and the first patients enrolled and dosed in Phase 1 clinical...

Special report: Twenty extraordinary women blazing trails in biopharma R&D — Covid-19 and beyond

In the second year of Endpoints News’  budding tradition of highlighting women blazing trails in biopharma R&D, we’ve seen a number of...

Dragonfly Therapeutics Announces the Publication of Preclinical Data

Supporting DF6002, its Extended Half-life IL-12 Cytokine, as a Promising Treatment for Cancer The publication titled "An optimized...

Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb

Today's announcement marks the first TriNKET opt-in outside of oncology. Dragonfly to receive a $25 million payment and is eligible to...

Dragonfly Announces First Patient Dosed in Clinical Trial with Merck Evaluating Solid Tumor Target

Milestone payment to Dragonfly is triggered by dosing of first patient in Phase 1 clinical trial Dragonfly Therapeutics, Inc....

Dragonfly Therapeutics Expands Clinical Leadership Team

Appointing Dr. Hesham Aboshady as Head of Safety & Pharmacovigilance and Rajesh Israni as Head of Regulatory Affairs. Hesham Aboshady MD,...

Merck buzzes Dragonfly for 2nd immunotherapy candidate in $700M pact

The dragon is flying high today as Merck hits go on a second immunotherapy candidate from its $700 million pact with Dragonfly...

Dragonfly Therapeutics Announces Merck Opt-In of TriNKET™ Immunotherapy Candidate for Patients

Merck executes option to license its second immunotherapy candidate from the companies' 2018 collaboration for solid tumor targets....

Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate

Dragonfly to receive payment for the first Opt-In from AbbVie as part of a multi-target collaboration launched just over 1 year ago.

Merck opts in for Dragonfly's TriNKET cancer immunotherapy program

The U.S. Big Pharma is getting its hands on its first TriNKET immunotherapy candidate from the biotech, which comes after the pair...

Dragonfly Announces it now owns all rights to its DF6002 novel IL12 cytokine

Dragonfly now wholly owns the IL12 cytokine, currently in mid-Phase 1 dose escalation as a monotherapy and in combination with nivolumab....

Dragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET™

Dragonfly also announced this week its first TriNKET, HER2-targeting DF1001, entered Phase 2. In its Phase 1 study DF1001 was...

Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engage

Gilead Sciences, Inc. (Nasdaq: GILD) and Dragonfly Therapeutics today announced a collaboration designed to advance a number of...

Bristol Myers partner comes through on IL-12 effort. Now it's Rupert Vessey's turn at bat

Two years ago, Bristol Myers Squibb R&D boss Rupert Vessey unveiled one of the biggest cash deals he’d done, focusing on the high-risk,...

Merck hits 'go' on a second Dragonfly drug

Merck & Co. Inc. has decided to move forward on its option to license a second drug from Waltham-based Dragonfly Therapeutics. The two...

Dragonfly Announces DF1001 Granted Orphan Drug Designation in the US for Esophageal Cancer

The company announces that its lead TriNKET™ immunotherapy program DF1001, a HER2-targeted NK cell engager therapy...

AbbVie selects target for Dragonfly partnership

Dragonfly’s partnership with AbbVie is beginning to bear fruit.

Merck’s Roger Perlmutter buys his first solid tumor TriNKET from Dragonfly

A little more than 2 years after Merck’s Roger Perlmutter signed off on a deal that would pay Dragonfly up to $695 million for each drug...